M7437

DRUG2 trials

Sponsors

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.

Conditions

Advanced Solid Tumors

Phase 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Not yet recruitingNCT07311603

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyAdvanced Solid Tumors

Start: 2026-01-02End: 2029-03-28Target: 138Updated: 2025-12-31

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

RecruitingNCT07360314

EMD Serono Research & Development Institute, Inc.Advanced Solid Tumors

Start: 2026-02-13End: 2029-03-28Target: 138Updated: 2026-09-09